New heart drug UDP-003 enters first human safety tests
NCT ID NCT06813339
First seen Mar 03, 2026 · Last updated Jun 19, 2026 · Updated 10 times
Summary
This early-stage trial tests whether an experimental drug called UDP-003 is safe in healthy volunteers and people with heart disease. Researchers will give single or multiple doses of the drug or a placebo and monitor for side effects. The study includes 84 participants and is the first time UDP-003 is tested in humans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX Clinical Research
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UDP-003 (an experimental drug given by IV injection)
What this could lead to
If safe and effective, UDP-003 could become a new treatment to control atherosclerotic cardiovascular disease and reduce heart attack risk.
What could go wrong
This is a very early (Phase 1) trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results in healthy people may not apply to patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.